
-
Moderna NasdaqGS:MRNA Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Location: 325 Binney Street, Cambridge, MA, 02142, United States | Website: https://www.modernatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.384B
Cash
5.975B
Avg Qtr Burn
-763M
Short % of Float
16.68%
Insider Ownership
7.28%
Institutional Own.
73.88%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
mRNA-1273 Details COVID-19 | Approved Quarterly sales | |
Spikevax® Details COVID-19 | Approved Quarterly sales | |
mRESVIA (mRNA-1345) Details Respiratory syncytial virus | PDUFA Approval decision | |
mRNA-1283 Details COVID-19 | PDUFA Approval decision | |
mRNA-1010 Details Influenza | BLA Submission | |
mRNA-1403 Details Norovirus, Gastroenteritis | Phase 3 Data readout | |
mRNA-4157/V940 +KEYTRUDA Details Melanoma, Cancer | Phase 3 Data readout | |
mRNA-4157/V940 +KEYTRUDA Details Cancer, Non-small cell lung carcinoma | Phase 3 Data readout | |
mRNA-1647 Details Cytomegalovirus | Phase 3 Data readout | |
mRNA-1083 Details COVID-19, Influenza | Phase 3 Update | |
mRNA-3705 Details Rare diseases, Methylmalonic acidemia | Phase 3 Initiation | |
mRNA-1468 Details Varicella-zoster virus | Phase 1/2 Data readout | |
mRNA-3927 Details Propionic acidemia | Phase 1/2 Update | |
mRNA-1574 Details Human immunodeficiency virus | Phase 1 Data readout |